Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

28.32USD
8:00pm GMT
Change (% chg)

$0.98 (+3.58%)
Prev Close
$27.34
Open
$27.55
Day's High
$28.55
Day's Low
$27.55
Volume
52,124
Avg. Vol
82,825
52-wk High
$40.60
52-wk Low
$17.74

About

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense... (more)

Overall

Beta: --
Market Cap(Mil.): $1,860.50
Shares Outstanding(Mil.): 66.54
Dividend: --
Yield (%): --

Financials

  AKCA.OQ Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -4.36 -- --
ROI: -- 14.23 13.82
ROE: -- 15.46 15.24

EU committee approves Akcea-Ionis drug for rare genetic disease

March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

01 Mar 2019

Novartis aims to pump up cardio business with Ionis deal

ZURICH Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

25 Feb 2019

UPDATE 2-Novartis aims to pump up cardio business with Ionis deal

* Novartis aims to build up heart drug portfolio (Adds comment from Novartis drug developer, details of payment and deal)

25 Feb 2019

BRIEF-Akcea Therapeutics Says Co Will Receive A $150 Mln License Fee That Will Be Split Equally With Ionis

* AKCEA-APO(A)-LRX ADVANCES AS LEADING PHARMACEUTICAL COMPANY EXERCISES OPTION TO LICENSE

25 Feb 2019

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

05 Oct 2018

Akcea Therapeutics genetic disease treatment gets FDA approval

Oct 5 Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

05 Oct 2018

Earnings vs. Estimates